Skip to main content
PLOS ONE logoLink to PLOS ONE
. 2015 Sep 25;10(9):e0138916. doi: 10.1371/journal.pone.0138916

Correction: Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature

David L Chan, Nick Pavlakis, Jeremy Shapiro, Timothy J Price, Christos S Karapetis, Niall C Tebbutt, Eva Segelov
PMCID: PMC4583271  PMID: 26406241

There is an error in reference 22. The correct reference is: Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y, et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan(FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastaticcolorectal cancer. J Clin Oncol. 2010 Nov 1;28(31):4706-13.

Fig 5 is incorrect. The authors have provided a corrected version here.

Fig 5. OS outcomes for EGFR-I by chemotherapy backbone—extended RAS analysis.

Fig 5

Reference

  • 1. Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, et al. (2015) Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS ONE 10(8): e0135599 doi:10.1371/journal.pone.0135599 [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from PLoS ONE are provided here courtesy of PLOS

RESOURCES